imiquimod has been researched along with Infections, Staphylococcal in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aljuffali, IA; Fang, JY; Huang, CW; Lee, WR; Lin, YK; Shen, SC | 1 |
| Cheng, G; Deng, JC; Ghaffari, AA; Lung, WY; Meyerson, C; Tian, X; Xu, F | 1 |
2 other study(ies) available for imiquimod and Infections, Staphylococcal
| Article | Year |
|---|---|
Non-ablative fractional laser assists cutaneous delivery of small- and macro-molecules with minimal bacterial infection risk.
Topics: Administration, Cutaneous; Aminolevulinic Acid; Aminoquinolines; Animals; Dextrans; Drug Delivery Systems; Fluorescein; Fluorescein-5-isothiocyanate; Imiquimod; Lasers, Solid-State; Mice, Inbred BALB C; Mice, Nude; Peptides; Pseudomonas aeruginosa; Pseudomonas Infections; Quantum Dots; Skin; Skin Absorption; Staphylococcal Infections; Staphylococcus aureus; Swine; Tretinoin | 2016 |
Poly I:C enhances susceptibility to secondary pulmonary infections by gram-positive bacteria.
Topics: Aminoquinolines; Animals; Antibodies; Antigens, Viral; Disease Susceptibility; Gene Expression Regulation; Imidazoles; Imiquimod; Interferon Inducers; Interferon Type I; Membrane Proteins; Methicillin-Resistant Staphylococcus aureus; Mice; Nerve Tissue Proteins; Pneumococcal Infections; Pneumonia, Bacterial; Poly I-C; Receptor, Interferon alpha-beta; Receptors, Cell Surface; Signal Transduction; Staphylococcal Infections; Streptococcus pneumoniae; Survival Rate; Toll-Like Receptor 3 | 2012 |